Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

289 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism.
Tanner CM, Cummings SR, Schwarzschild MA, Brown EG, Dorsey ER, Espay AJ, Galifianakis NB, Goldman SM, Litvan I, Luthra N, McFarland NR, Mitchell KT, Standaert DG, Bauer DC, Greenspan SL, Beck JC, Lyles KW. Tanner CM, et al. Among authors: standaert dg. NPJ Parkinsons Dis. 2021 Mar 1;7(1):16. doi: 10.1038/s41531-021-00162-1. NPJ Parkinsons Dis. 2021. PMID: 33649343 Free PMC article.
Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.
Nalls MA, McLean CY, Rick J, Eberly S, Hutten SJ, Gwinn K, Sutherland M, Martinez M, Heutink P, Williams NM, Hardy J, Gasser T, Brice A, Price TR, Nicolas A, Keller MF, Molony C, Gibbs JR, Chen-Plotkin A, Suh E, Letson C, Fiandaca MS, Mapstone M, Federoff HJ, Noyce AJ, Morris H, Van Deerlin VM, Weintraub D, Zabetian C, Hernandez DG, Lesage S, Mullins M, Conley ED, Northover CA, Frasier M, Marek K, Day-Williams AG, Stone DJ, Ioannidis JP, Singleton AB; Parkinson's Disease Biomarkers Program and Parkinson's Progression Marker Initiative investigators. Nalls MA, et al. Lancet Neurol. 2015 Oct;14(10):1002-9. doi: 10.1016/S1474-4422(15)00178-7. Epub 2015 Aug 10. Lancet Neurol. 2015. PMID: 26271532 Free PMC article.
Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.
Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, Brundin P, Kauffman MA, Erro R, Kieburtz K, Woo D, Macklin EA, Standaert DG, Lang AE. Espay AJ, et al. Among authors: standaert dg. Mov Disord. 2017 Mar;32(3):319-324. doi: 10.1002/mds.26913. Epub 2017 Feb 24. Mov Disord. 2017. PMID: 28233927 Free PMC article. Review.
Genetic influences on cognition in progressive supranuclear palsy.
Gerstenecker A, Roberson ED, Schellenberg GD, Standaert DG, Shprecher DR, Kluger BM, Litvan I. Gerstenecker A, et al. Among authors: standaert dg. Mov Disord. 2017 Dec;32(12):1764-1771. doi: 10.1002/mds.27196. Epub 2017 Oct 27. Mov Disord. 2017. PMID: 29076559 Free PMC article.
Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease.
Fernandez HH, Boyd JT, Fung VSC, Lew MF, Rodriguez RL, Slevin JT, Standaert DG, Zadikoff C, Vanagunas AD, Chatamra K, Eaton S, Facheris MF, Hall C, Robieson WZ, Benesh J, Espay AJ. Fernandez HH, et al. Among authors: standaert dg. Mov Disord. 2018 Jul;33(6):928-936. doi: 10.1002/mds.27338. Epub 2018 Mar 23. Mov Disord. 2018. PMID: 29570853 Clinical Trial.
289 results